You are here

P&T® Journal contents for May 2005


Health Care & Law
Some think that it might be time to add a new class of drugs to the existing categories.
Robert I. Field, JD, MPH, PhD
Analyzing patients’ prescription and medical claims from a managed care organization, the authors evaluate the risk of heart failure after TZD therapy.
Fadia T. Shaya, PhD, MPH, James Y. Shin, PharmD, C. Daniel Mullins, PhD, Antoine C. El Khoury, PhD, and Howard Garber, MD, MPH
Drug Class Review
Drs. McCarthy and Caspi describe the benefits and risks of intravenous and oral PPIs and the considerations regarding their inclusion on formularies.
Denis M. McCarthy, MD, PhD, MSc, and Alan Caspi, PhD, PharmD, MBA
Case Study
The authors describe the use of telemedicine and telepharmacy to provide drug delivery to low-income, underserved segments of the population.
LoriAnn Collins, RPh, MBA, Charles J. Quigley, Jr., PhD, and Frank G. Bingham, Jr., EdD
The authors illustrate their discussion of cancer-related and non–cancer-related pain in a pertinent case study with an emphasis on pharmacological management.
Daniel Bennett, MD, Allen W. Burton, MD, Scott Fishman, MD, Barry Fortner, PhD, Bill McCarberg, MD, Chris Miaskowski, PhD, RN, David B. Nash, MD, MBA, Marco Pappagallo, MD, Richard Payne, MD, James Ray, PharmD, Eugene R. Viscusi, MD, and Winston Wong, PharmD


David Nash, MD, MBA, summarizes one institution’s guidelines for relationships between employees in academic medicine and pharmaceutical sales representatives.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses the increased risk of errors resulting from poorly labeled plastic ampules for nebulizing agents.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the Safety and Quality Improvement Act of 2005, which is intended to help decrease medical errors.
Stephen Barlas
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
The authors review the benefits of increased compliance and decreased pill burden with Truvada™ for treating HIV infection.
Evans Branch III, PharmD, Marlon Honeywell, PharmD, Wayne Simon, PharmD, Anishka Richardson, PharmD, and Muideen Adigun, PharmD Candidate